ME-344

Generic Name: ME-344

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₀O_₄

CAS Number: 1374524-68-1

Unique Ingredient Identifier: 843G0TDV51

Background: ME-344 has been used in trials studying the treatment of Solid Tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: ME-344
Drug: Bevacizumab

First Posted Date: 2023-04-21

Last Posted Date: 2024-11-21

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 23

Registration Number: NCT05824559

Locations: 🇺🇸
Rutgers University, New Brunswick, New Jersey, United States
🇺🇸
Mt Sinai New York, New York, New York, United States
🇺🇸
Vanderbilt -Ingram Cancer Center, Nashville, Tennessee, United States

and more 4 locations

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Early Phase 1

Completed

Conditions: Early-Stage Breast Carcinoma
Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: ME-344
Other: Normal saline
Drug: Bevacizumab

First Posted Date: 2016-06-21

Last Posted Date: 2019-07-23

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 40

Registration Number: NCT02806817

Locations: 🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇪🇸
H. Arnau de Vilanova Lleida, Lleida, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 2 locations

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: ME-344
Drug: Topotecan

First Posted Date: 2014-03-31

Last Posted Date: 2017-10-02

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 46

Registration Number: NCT02100007

Locations: 🇬🇧
The Bays St Mary's Hospital, London, England, United Kingdom
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 7 locations

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

First Posted Date: 2012-03-05

Last Posted Date: 2015-06-18

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 24

Registration Number: NCT01544322

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy